According to a recent LinkedIn post from Briya, the company is using the Informa Connect BIO-Europe Spring conference in Lisbon to engage with European biotech innovators. The post highlights plans to discuss emerging therapies, strategic partnerships, and approaches to driving scalable growth and long-term value.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Briya is positioning its AIRE platform as a tool that combines access to global, high-quality real-world data with AI-enhanced research capabilities. This focus on data-driven decision-making across the R&D lifecycle, from protocol design and feasibility to chart reviews and real-world evidence generation, may support the company’s role in biopharma analytics and strengthen its appeal as a potential partner for development-stage and commercial organizations.